|UNITED STATESSECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-Q/A(Amendment No. 1)


[  X  ] Quarterly Report pursuant
to Section 13 or 15(d) of the Securities
Exchange Act of 1934For the quarterly period ended June 30, 2003

[   ] Transition Report
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934

For the transition period from ___ to ___

Commission File Number  0-26138
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | Dendrite International, Inc. | 
| | ---------------------------- | 

| | (Exact name of registrant as specified in its charter) | 
| | ------------------------------------------------------ | 

|New Jersey |  | 22-2786386
|---------- |  | ----------

|(State or other jurisdiction of 
incorporation or organization) |  | (I.R.S. Employer Identification No.)
|--------------------------------------------------------------- |  | ------------------------------------

|1200 Mount Kemble Avenue
Morristown, NJ 07960
(Address, including zip code, of
principal executive offices)




(973) 425-1200
(Registrants telephone number, including area code)



Indicate by check mark whether the  registrant:
(1) has filed all reports  required to be filed by Section 13 or 15(d) of the  Securities  Exchange Act of 1934 during the  preceding  12 months (or for such
shorter period that the registrant was required to file such reports),  and (2) has been subject to such filing  requirements  for
the past 90 days.    [  X  ]


Indicate by check mark
whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act):
    [  X  ]


Indicate the number of shares outstanding of each of the
issuers classes of common stock, as of the last practicable date: at August 11, 2003 there were 40,419,646 shares of
common stock outstanding.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

---

|DENDRITE INTERNATIONAL, INC.
INDEX
|----------------------------------

|                                           | PAGE NO.
|------------------------------------------ | --------
|                                           |         
|Explanatory Note                           |         
|                                           |         
|ITEM 6.   Exhibits and Reports on Form 8-K |         
|                                           |         
|Signatures                                 |         

---

|Explanatory Note



This Form 10-Q/A amends Item 6
and exhibits 31.1 and 31.2 of the Dendrite International, Inc. Quarterly Report on Form
10-Q for the quarter ended June 30, 2003, filed on August 14, 2003, to correct an
error made during the EDGARizing of the form of Section 302 Sarbanes-Oxley certifications
filed as exhibits 31.1 and 31.2 to the Form 10-Q. The
correct form of Section 302 certifications had in fact been executed by the CEO and CFO of
the Company at the time the Quarterly Report on Form 10-Q was originally filed on
August 14, 2003. However, the EDGARized version of the Form 10-Q mistakenly did not
contain the correct form of Section 302 certifications. This amendment also includes Exhibit 10.44 which was listed as an
exhibit but was inadvertently omitted from the Form 10-Q in connection with the Northeast power outage on August 14, 2003.
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

---

|ITEM 6.     
Exhibits and Reports on Form 8-K


(i)    Exhibits
|---------------------------------------------------------------

| |  | 10.39 |  | Distribution Agreement between IMS Health Incorporated and Synavant Inc. dated as of
August 31, 2000.
| |  | ----- |  | -----------------------------------------------------------------------------------------------------

| |  | 10.40 |  | Amendment
to Distribution Agreement between IMS Health Incorporated and Synavant Inc. dated as of
June 16, 2003.
| |  | ----- |  | ----------------------------------------------------------------------------------------------------------------

| |  | 10.41 |  | Restated Xponent Data License Agreement between IMS Health  Incorporated and Synavant
Inc. dated as of April                   26, 2001.
| |  | ----- |  | ----------------------------------------------------------------------------------------------------------------------------------------

| |  | 10.42 |  | Amendment
to Restated Xponent Data License  Agreement  between IMS Health  Incorporated,  Synavant
Inc. and Dendrite                   International, Inc. dated as of June 16, 2003.
| |  | ----- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | 10.43 |  | Synavant
Inc. 2000 Savings Equalization Plan.
| |  | ----- |  | ---------------------------------------------

| |  | 10.44 |  | Cross License between IMS Health Incorporated and
Synavant Inc. dated as of August 31, 2000.
| |  | ----- |  | --------------------------------------------------------------------------------------------

| |  | 31.1 |  | Certification
 of John E.  Bailye,  Chairman of the Board and Chief  Executive  Officer of the
 Company,  pursuant to Securities Exchange Act Rule 13a-14(a) dated August 13, 2003.
| |  | ---- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | 31.2 |  | Certification
of Kathleen E. Donovan,  Senior Vice President and Chief Financial Officer of the
Company,  pursuant to  Securities Exchange Act Rule 13a-14(a) dated August 13, 2003.
| |  | ---- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | 31.3 |  | Certification
 of John E.  Bailye,  Chairman of the Board and Chief  Executive  Officer of the
 Company,  pursuant to Securities Exchange Act Rule 13a-14(a) dated August 18, 2003.
| |  | ---- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | 31.4 |  | Certification
of Kathleen E. Donovan,  Senior Vice President and Chief Financial Officer of the
Company,  pursuant to  Securities Exchange Act Rule 13a-14(a) dated August 18, 2003.
| |  | ---- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | 32.1 |  | Certifications
 Pursuant to 18 U.S.C.  Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, signed by John E. Bailye,  Chairman of the
Board and Chief Executive  Officer of the Company,  and Kathleen E.
Donovan, Senior Vice President and Chief Financial Officer of the
Company dated August 13, 2003.
| |  | ---- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | 32.2 |  | Certifications
 Pursuant to 18 U.S.C.  Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, signed by John E. Bailye,  Chairman of the
Board and Chief Executive  Officer of the Company,  and Kathleen E.
Donovan, Senior Vice President and Chief Financial Officer of the
Company dated August 18, 2003.
| |  | ---- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(ii)                 Reports
on Form 8-K
|----------------------------------------

|(a) |  | The Company filed a Current Report on Form 8-K on July 1, 2003, pursuant to
               Item 2. Acquisition or Disposition of Assets and Item 7.
               Financial Statements, Pro Forma Financial Information and Exhibits
               relating to its acquisition of Synavant Inc.
|--- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(b) |  | The Company filed a Current Report on Form 8-K on June 20, 2003, pursuant to
               Item 5. Other Events and Regulation FD Disclosure and Item 7.
               Financial Statements, Pro Forma Financial Information and Exhibits
               relating to a credit agreement by and among the Company, certain lenders and
               JPMorgan Chase Bank.
|--- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(c) |  | The Company filed a Current Report on Form 8-K on May 20, 2003, pursuant to
               Item 5. Other Events and Regulation FD Disclosure and Item 7.
               Financial Statements, Pro Forma Financial Information and Exhibits
               relating to an amendment to the Agreement and Plan of Merger by and among the
               Company, Synavant Inc. and Amgis Acquisition Co. and a promissory note by and
               between the Company and Synavant Inc.
|--- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(d) |  | The Company filed a Current Report on Form 8-K on May 19, 2003, pursuant to
               Item 5. Other Events and Regulation FD Disclosure and Item 7.
               Financial Statements, Pro Forma Financial Information and Exhibits
               relating to an amendment to the Agreement and Plan of Merger by and among the
               Company, Synavant Inc. and Amgis Acquisition Co.
|--- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(e) |  | The Company filed a Current Report on Form 8-K on May 12, 2003, pursuant to
               Item 5. Other Events and Regulation FD Disclosure and Item 7.
               Financial Statements, Pro Forma Financial Information and Exhibits
               relating to the Agreement and Plan of Merger by and among the Company, Synavant
               Inc. and Amgis Acquisition Co.
|--- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(f) |  | The Company furnished a Current Report on Form 8-K on April 24, 2003, pursuant
               to Item 7. Financial Statements, Pro Forma Financial Information and
               Exhibits, Item 9. Regulation FD Disclosure and Item 12.
               Results of Operations and Financial Condition relating to its financial
               results for the first quarter of 2003.
|--- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|
|

---

|Signatures


Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.



Date: August 18, 2003
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | By:  KATHLEEN E. DONOVAN
Kathleen E. Donovan, Senior Vice President
and Chief Financial Officer
(Principal Financial Officer)
| |  | -------------------------------------------------------------------------------------------------------------------------------------------

---

|EXHIBIT INDEX
|-------------

| |  | Number |  | Description
| |  | ------ |  | -----------

| |  | 10.39 |  | Distribution Agreement between IMS Health Incorporated and Synavant Inc. dated as of
August 31, 2000.
| |  | ----- |  | -----------------------------------------------------------------------------------------------------

| |  | 10.40 |  | Amendment
to Distribution Agreement between IMS Health Incorporated and Synavant Inc. dated as of
June 16, 2003.
| |  | ----- |  | ----------------------------------------------------------------------------------------------------------------

| |  | 10.41 |  | Restated Xponent Data License Agreement between IMS Health  Incorporated and Synavant
Inc. dated as of April                   26, 2001.
| |  | ----- |  | ----------------------------------------------------------------------------------------------------------------------------------------

| |  | 10.42 |  | Amendment
to Restated Xponent Data License  Agreement  between IMS Health  Incorporated,  Synavant
Inc. and Dendrite                   International, Inc. dated as of June 16, 2003.
| |  | ----- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | 10.43 |  | Synavant
Inc. 2000 Savings Equalization Plan.
| |  | ----- |  | ---------------------------------------------

| |  | 10.44 |  | Cross License between IMS Health Incorporated and
Synavant Inc. dated as of August 31, 2000.
| |  | ----- |  | --------------------------------------------------------------------------------------------

| |  | 31.1 |  | Certification
 of John E.  Bailye,  Chairman of the Board and Chief  Executive  Officer of the
 Company,  pursuant to Securities Exchange Act Rule 13a-14(a) dated August 13, 2003.
| |  | ---- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | 31.2 |  | Certification
of Kathleen E. Donovan,  Senior Vice President and Chief Financial Officer of the
Company,  pursuant to  Securities Exchange Act Rule 13a-14(a) dated August 13, 2003.
| |  | ---- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | 31.3 |  | Certification
 of John E.  Bailye,  Chairman of the Board and Chief  Executive  Officer of the
 Company,  pursuant to Securities Exchange Act Rule 13a-14(a) dated August 18, 2003.
| |  | ---- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | 31.4 |  | Certification
of Kathleen E. Donovan,  Senior Vice President and Chief Financial Officer of the
Company,  pursuant to  Securities Exchange Act Rule 13a-14(a) dated August 18, 2003.
| |  | ---- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | 32.1 |  | Certifications
 Pursuant to 18 U.S.C.  Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, signed by John E. Bailye,  Chairman of the
Board and Chief Executive  Officer of the Company,  and Kathleen E.
Donovan, Senior Vice President and Chief Financial Officer of the
Company dated August 13, 2003.
| |  | ---- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | 32.2 |  | Certifications
 Pursuant to 18 U.S.C.  Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, signed by John E. Bailye,  Chairman of the
Board and Chief Executive  Officer of the Company,  and Kathleen E.
Donovan, Senior Vice President and Chief Financial Officer of the
Company dated August 18, 2003.
| |  | ---- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------